CORRESP Filing
TENAX THERAPEUTICS, INC.
Date: April 21, 2025 · CIK: 0000034956 · Accession: 0001654954-25-004482
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286557
Letter
tennx_corresp.htm TENAX THERAPEUTICS, INC. 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 April 21, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286557 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tenax Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the registration statement on Form S-3 (File No. 333-286557) (the “Registration Statement”), of the Registrant, relating to the registration of certain of the Registrant’s securities, so that it may become effective on Wednesday, April 23, 2025 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable. In connection with the foregoing, the Registrant hereby acknowledges the following: · should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and · the Registrant will not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please be advised that there are no underwriters or sales agents involved as the Registration Statement is for a resale offering by selling stockholders. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Lorna Knick at (919) 865-2823. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to our counsel via e-mail at lknick@wyrick.com. Sincerely, TENAX THERAPEUTICS, INC. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm tennx_corresp.htm TENAX THERAPEUTICS, INC. 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 April 21, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286557 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tenax Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the registration statement on Form S-3 (File No. 333-286557) (the “Registration Statement”), of the Registrant, relating to the registration of certain of the Registrant’s securities, so that it may become effective on Wednesday, April 23, 2025 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable. In connection with the foregoing, the Registrant hereby acknowledges the following: · should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and · the Registrant will not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please be advised that there are no underwriters or sales agents involved as the Registration Statement is for a resale offering by selling stockholders. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Lorna Knick at (919) 865-2823. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to our counsel via e-mail at lknick@wyrick.com. Sincerely, TENAX THERAPEUTICS, INC. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer